Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kylie Money

Physician Assistant Ogden, UT Physician Assistant

NPI 1871058131 CMS profile 10438010

5290 S 400 E, Ogden, UT 84405

Open in the dashboard

General payments

$24,516

763 records reported · program years 2021–2025

Research payments

$4,327

Paid to them · 31 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kylie Money of Ogden, UT is reported in the CMS Open Payments database as having received $24,516 across 763 general payments and $4,327 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,851 164
2025 Research $1,653 14
2024 General $8,151 217
2024 Research $2,674 17
2023 General $5,096 166
2022 General $4,313 127
2021 General $2,104 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kylie Money
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kylie Money were reported at $4,851. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kylie Money Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,104 $132 $37–$438 $132
2022 $4,313 $155 $48–$522 $149
2023 $5,096 $167 $52–$557 $160
2024 $8,151 $178 $55–$600 $164
2025 $4,851 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $4,635 111 payments
  2. Eli Lilly and Company $2,475 1 payment
  3. G1 Therapeutics, Inc. $1,365 4 payments
  4. AstraZeneca Pharmaceuticals LP $1,267 44 payments
  5. Janssen Biotech, Inc. $1,149 43 payments
  6. Daiichi Sankyo Inc. $1,047 40 payments
  7. Genentech USA, Inc. $830 29 payments
  8. Seattle Genetics, Inc. $660 16 payments
  9. Genzyme Corporation $658 19 payments
  10. Incyte Corporation $625 17 payments
  11. Other $9,805 439 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,994 706 payments
  2. Long term medical supply or device loan $2,498 29 payments
  3. Consulting Fee $2,475 1 payment
  4. Education $1,520 20 payments
  5. Travel and Lodging $1,028 6 payments
  6. Honoraria $1,000 1 payment
Products named General payments · program years 2021–2025
  1. VERZENIO $2,789 16 payments
  2. KISQALI $2,497 48 payments
  3. COSELA $1,386 5 payments
  4. ENHERTU $703 28 payments
  5. KEYTRUDA $560 26 payments
  6. LIBTAYO $552 20 payments
  7. BRUKINSA $487 11 payments
  8. LYNPARZA $427 4 payments
  9. JAKAFI $402 11 payments
  10. POLIVY $379 11 payments
  11. Other $15,367 766 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Regeneron Pharmaceuticals, Inc. $2,674 17 payments
  2. AbbVie, Inc. $1,653 14 payments

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

655

Median for Physician Assistant: 241

Drug cost

$364,511

Median for Physician Assistant: $4,110

Branded share of claims

35.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cabometyx Cabozantinib S-Malate Brand 12 $300,877
Eliquis Apixaban Brand 36 $30,394
Xarelto Rivaroxaban Brand 23 $15,217
Enoxaparin Sodium Generic 11 $6,274
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 53 $1,988
Fentanyl Generic 19 $1,737
Tamoxifen Citrate Generic 27 $1,131
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 21 $812
Hydroxyurea Generic 20 $694
Letrozole Generic 26 $596

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 157 billing codes

Paid by Medicare

$1,001,162

Of which drugs: $856,285

Medicare patients

387

Average age 75

Services billed

75,804

232 women, 155 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Cancer 50%
Arthritis 40%
Chronic kidney disease 37%
Diabetes 29%
Ischemic heart disease 24%
Depression 23%
Osteoporosis 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, nivolumab, 1 mg J9299 Office 12 8,520 $209,298
Injection, denosumab, 1 mg J0897 Office 12 1,500 $30,820
Injection, aprepitant, 1 mg J0185 Office 16 2,860 $3,866
Injection, palonosetron hcl, 25 mcg J2469 Office 20 410 $290
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 33 940 $85
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 35 $33
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 14 360 $26
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 21 37 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 84 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERZENIO
$2,516 — —
KISQALI
$1,084 — —
ENHERTU
$328 — —
CARVYKTI
$223 — —
KEYTRUDA
$194 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 84 with Patron

Records

794 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record